Pfizer Inc (PFE)

Currency in USD
29.23
-0.16(-0.54%)
Closed·
29.28+0.05(+0.17%)
·
High dividend Yield
PFE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
28.9829.63
52 wk Range
23.6231.44
Key Statistics
Prev. Close
29.23
Open
29.59
Day's Range
28.98-29.63
52 wk Range
23.62-31.44
Volume
45.77M
Average Volume (3m)
33.91M
1-Year Change
19.8442%
Book Value / Share
15.62
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PFE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
30.26
Upside
+3.52%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Pfizer Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Analyst Ratings

9 Buy
17 Hold
2 Sell
Ratings:
28 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 30.26
(+3.52% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Freedom Broker
Buy34.00+16.32%33.00Maintain06-11-2026
DZ Bank
Hold33.00+12.90%-Downgrade06-11-2026
Argus
Buy40.00+36.85%35.00Maintain04-11-2026
Morgan Stanley
Hold26.00-11.05%28.00Maintain04-11-2026
UBS
Hold30.00+2.63%27.00Maintain04-11-2026

Pfizer Inc SWOT Analysis


Oncology Ambitions
Pfizer's strategic focus on oncology, bolstered by acquisitions and pipeline developments, aims to offset challenges from patent expirations and drive future growth
Financial Resilience
Despite market challenges, Pfizer maintains strong profitability with a 73.8% gross profit margin and a 7.15% dividend yield, signaling long-term financial stability
Regulatory Headwinds
Navigate the impact of healthcare reforms and the Inflation Reduction Act on Pfizer's operations, including an $825 million hit in Q2 2025 from Medicare Part D changes
Valuation Insights
With a consensus 'Hold' rating and price targets ranging from $24 to $30, Pfizer's current stock price of $24.5 suggests potential undervaluation in the market
Read full SWOT analysis

Pfizer Inc Earnings Call Summary for Q3/2026

  • Pfizer Q3 2026 adjusted EPS of $0.87 beat consensus by 19%; revenue of $16.6B topped estimates by 4.34%, driven by strong commercial execution.
  • Company raised FY 2026 guidance to $62-64B revenue and $2.95-3.05 EPS, citing 32% operational growth in launched/acquired products like PADCEV.
  • Non-COVID products grew 7% operationally; Seagen integration progressing with portfolio up 39% YoY, supporting transition from pandemic-era sales.
  • Pfizer targeting $7.2B net savings by end-2026, plus additional $2.5B through 2029 to offset patent expiration pressures on IBRANCE, ELIQUIS.
  • Stock fell 0.72% premarket despite beat; investors focused on LOE risks, premium 40x P/E valuation, and need for pipeline execution to sustain growth.
Last Updated: 03-11-2026, 09:56 pm
Read Full Transcript

Earnings

Latest Release
03-11-2026
EPS / Forecast
0.87 / 0.73
Revenue / Forecast
16.6B / 15.91B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 0.71
Dividend Yield
5.88%
Industry Median 2.14%
Annualised payout
1.72
Paid quarterly
5-Years Growth
+6.76%
Growth Streak

PFE Income Statement

Compare PFE to Peers and Sector

Metrics to compare
PFE
Peers
Sector
Relationship
P/E Ratio
41.3x25.8x−0.2x
PEG Ratio
−0.70−0.230.00
Price/Book
1.9x2.3x2.6x
Price / LTM Sales
2.6x3.1x2.8x
Upside (Analyst Target)
3.5%0.0%60.9%
Fair Value Upside
Unlock9.5%9.5%Unlock

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Employees
75000

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.86B32.70%54.78B
Other Institutional Investors
2.02B35.45%59.39B
Public Companies & Retail Investors
1.82B31.85%53.35B
Total
5.7B100.00%167.52B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.9.29%52,96,70,4331,55,67,014
Vanguard Capital Management, LLC7.09%40,41,55,7211,18,78,137

FAQ

What Is the Pfizer (PFE) Share Price Today?

The Pfizer share price today is 29.23.

What is the current Pfizer (PFE) share price and day range?

As of 10-11-2026, the Pfizer share price is 29.23, with a previous close of 29.23. The share price has ranged from 28.98 to 29.63 today, while the 52-week range spans from 23.62 to 31.44.

What Is the Pfizer Market Cap?

As of today, Pfizer market cap is 166.61B.

Does Pfizer Pay Dividends? What's The Current Dividend Yield?

The Pfizer dividend yield is 5.9%%.

What Is the Pfizer (PFE) Share Price Target?

The average 12-month share price target for Pfizer is 30.26, with a high estimate of 37 and a low estimate of 25. 9 analysts recommend buying, while 2 suggest selling, with an overall rating of Buy and +3.52% Upside potential.

What Is Pfizer's Earnings Per Share (TTM)?

The Pfizer EPS (TTM) is 0.71.

When Is the Next Pfizer Earnings Date?

Pfizer will release its next earnings report on 02-02-2027.

From a Technical Analysis Perspective, Is PFE a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.

What Stock Exchange Does Pfizer Trade On?

Pfizer is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Pfizer?

The stock symbol for Pfizer is "PFE."

How Many Times Has Pfizer Stock Split?

Pfizer has split 6 times.

How Many Employees Does Pfizer Have?

Pfizer has 75000 employees.

What Is the PFE Premarket Price?

PFE's last pre-market stock price is 29.28. The pre-market share volume is 13,820.00, and the stock has changed by 0.05, or 0.17%.

What Is the PFE After Hours Price?

PFE's last after hours stock price is 29.35, the stock has changed by 0.12, or 0.41%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.